We are analyzing https://link.springer.com/article/10.1007/s13311-017-0519-x.

Title:
Glioma Subclassifications and Their Clinical Significance | Neurotherapeutics
Description:
The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, google, scholar, gliomas, tumors, idh, mutations, cas, molecular, central, mutation, glioma, classification, survival, cancer, clinical, gbm, patients, subtypes, mgmt, grade, braf, tumor, methylation, glioblastoma, prognosis, cell, gbms, oncol, cells, promoter, iii, based, diagnosis, ependymomas, alterations, prognostic, therapy, tert, analysis, therapies, temozolomide, studies, treatment, gene, trials, years, identified, genetic, group,

Topics {✒️}

nuclear factor κ-light-chain-enhancer canonical nf-κb signalling veliparib-mediated temozolomide-sensitizing therapy chimeric antigen receptor causing double-strand breaks high-affinity monoclonal antibody hypoxia-related proline hydroxylases raf-erk signaling pathway egfr-targeting therapies include gov/ct2/show/nct02573324 braf v600e-targeted therapy serine/threonine protein kinase cpg-rich region results idh wild-type counterparts central nervous system o6-methylguanine adducts induced tert wild-type tumor 1p/19q status “informally” pediatric high-grade glioma tumor necrosis factor-α o6-methylguanine-dna methyltransferase extra-cerebellar pilocytic astrocytoma anti-egfrviii vaccine c11orf95–rela fusions resulted validated 1p/19q deletion idh wild-type gliomas endogenous t-cell responses matthew smith-cohn anaplastic-level diffuse gliomas pediatric low-grade gliomas diffuse lower-grade gliomas idh wild-type gbm intact chromosome 1p/19q gene methylation-based subtyping idh1/idh2 wild-type adult low-grade gliomas separate amino-acid substitution concomitant low-grade astrocytoma mixed neuronal-glial tumors nf-κb pathways receptor tyrosine kinase idh wild-type lggs braf inhibitor therapy chromosome 1p/19q deletion 1p/19q-intact tumors [27] world health organization chromosome 1p/19q loss egfr-targeted therapy dna-repair gene mgmt progression-free survival ranging

Questions {❓}

Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas-same entity or first cousins?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Glioma Subclassifications and Their Clinical Significance
         description:The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.
         datePublished:2017-03-09T00:00:00Z
         dateModified:2017-03-09T00:00:00Z
         pageStart:284
         pageEnd:297
         sameAs:https://doi.org/10.1007/s13311-017-0519-x
         keywords:
            Glioma
            Ependymoma
            Targeted therapy
            IDH mutation
            MGMT methylation
            TERT promoter
            EGFR
            BRAF
            1p/19q co-deletion
            2HG
            MR spectroscopy
            Vaccine therapy
            Neurosciences
            Neurology
            Neurosurgery
            Neurobiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig3_HTML.gif
         isPartOf:
            name:Neurotherapeutics
            issn:
               1878-7479
               1933-7213
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ricky Chen
               affiliation:
                     name:University of Utah
                     address:
                        name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthew Smith-Cohn
               affiliation:
                     name:University of Utah
                     address:
                        name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adam L. Cohen
               affiliation:
                     name:University of Utah
                     address:
                        name:Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Howard Colman
               affiliation:
                     name:University of Utah
                     address:
                        name:Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center, University of Utah, Salt Lake City, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Glioma Subclassifications and Their Clinical Significance
      description:The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy (temozolomide and PCV [procarbazine, lomustine, vincristine]), and tumor-treating fields, are based on nonspecific targeting of proliferating cells. Recent advances in the molecular understanding of gliomas suggest some potential reasons for the failure of more targeted therapies in gliomas. Specifically, the histologic-based glioma classification is composed of multiple different molecular subtypes with distinct biology, natural history, and prognosis. As a result of these insights, the diagnosis and classification of gliomas have recently been updated by the World Health Organization. However, these changes and other novel observations regarding glioma biomarkers and subtypes highlight several clinical challenges. First, the field is faced with the difficulty of reinterpreting the results of prior studies and retrospective data using the new classifications to clarify prognostic assessments and treatment recommendations for patients. Second, the new classifications and insights require rethinking the design and stratification of future clinical trials. Last, these observations provide the essential framework for the development and testing of new specific targeted therapies for particular glioma subtypes. This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field.
      datePublished:2017-03-09T00:00:00Z
      dateModified:2017-03-09T00:00:00Z
      pageStart:284
      pageEnd:297
      sameAs:https://doi.org/10.1007/s13311-017-0519-x
      keywords:
         Glioma
         Ependymoma
         Targeted therapy
         IDH mutation
         MGMT methylation
         TERT promoter
         EGFR
         BRAF
         1p/19q co-deletion
         2HG
         MR spectroscopy
         Vaccine therapy
         Neurosciences
         Neurology
         Neurosurgery
         Neurobiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13311-017-0519-x/MediaObjects/13311_2017_519_Fig3_HTML.gif
      isPartOf:
         name:Neurotherapeutics
         issn:
            1878-7479
            1933-7213
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ricky Chen
            affiliation:
                  name:University of Utah
                  address:
                     name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthew Smith-Cohn
            affiliation:
                  name:University of Utah
                  address:
                     name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adam L. Cohen
            affiliation:
                  name:University of Utah
                  address:
                     name:Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Howard Colman
            affiliation:
                  name:University of Utah
                  address:
                     name:Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center, University of Utah, Salt Lake City, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Neurotherapeutics
      issn:
         1878-7479
         1933-7213
      volumeNumber:14
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Utah
      address:
         name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
         type:PostalAddress
      name:University of Utah
      address:
         name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
         type:PostalAddress
      name:University of Utah
      address:
         name:Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
         type:PostalAddress
      name:University of Utah
      address:
         name:Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center, University of Utah, Salt Lake City, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ricky Chen
      affiliation:
            name:University of Utah
            address:
               name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
      name:Matthew Smith-Cohn
      affiliation:
            name:University of Utah
            address:
               name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
      name:Adam L. Cohen
      affiliation:
            name:University of Utah
            address:
               name:Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
      name:Howard Colman
      affiliation:
            name:University of Utah
            address:
               name:Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center, University of Utah, Salt Lake City, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
      name:Department of Neurology, Clinical Neurosciences Center, University of Utah, Salt Lake City, USA
      name:Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
      name:Department of Neurosurgery, Huntsman Cancer Institute and Clinical Neuroscience Center, University of Utah, Salt Lake City, USA

External Links {🔗}(289)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref
Pbgrd

4.91s.

LINK . SPRINGER . COM {}